Measles elimination status Rubella elimination status
Total population 2 882 740
< 1 year old 34 405
< 5 years old 173 109
Demographic information, 2018
Source: World Population Prospects: The 2019 Revision, New York, United Nations
Measles and rubella surveillance National case-based surveillance for measles, rubella and CRS
Lab confirmation for diagnosis of measles, rubella and CRS
Source: WHO/UNICEF Joint Reporting Form on immunization, 2018
Measles and rubella elimination country profile Albania
Measles and rubella immunization schedule, 2018
Source: WHO/UNICEF Joint Reporting Form on immunization, 2018
MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine;
MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine
Measles and rubella cases and immunization coverage, 2009–2018
Source: WHO/UNICEF Joint Reporting Form on immunization, 2018 and WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), 2018
MCV1 = first dose of measles-containing vaccine MCV2= second dose of measles-containing vaccine
Definition used for an outbreak
Source: Measles and rubella elimination Annual Status Update report, 2018
At least two measles or rubella cases including cases with epidemiological links
2017 eliminated
2018 eliminated
Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: http://www.euro.who.int/8thRVC
Confirmed measles cases by month of onset, 2014-2018
Source: CISID, 2018
Vaccine Schedule
MCV1 MMR 1 year
MCV2 MMR 5 years
Year of introduction
MCV2 2001
RCV 2001
Measles vaccination in school ND
2017 eliminated
2018 re-established
Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: http://www.euro.who.int/8thRVC
0 10 20 30 40 50 60 70 80 90 100
0 200 400 600 800 1000 1200 1400 1600
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
% coverage
Number of cases
Year
Measles Rubella Coverage MCV1 Coverage MCV2
0 50 100 150 200 250 300 350 400
J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D
2014 2015 2016 2017 2018
Number of cases
Month and year
Albania
Informa�on on CRS, 2018
No cases reported
CRS = congenital rubella syndrome
Measles cases by first subna�onal level, 2018
Source:
Measles genotypes by first subna�onal level, 2018
Source: MeaNS, 2018
Sources of infec�on, 2018
Measles Rubella
Imported 21 0
Import-related 7 0
Endemic 1339 0
Unknown/ Not
reported 102 0
Source:
Source:
Note: Excludes imported cases
1dot=1case
•
B3•
D8•
H1•
D90 10 20 30 40 50 60 70 80 90 100
<1 1-4 5-9 10-14 15-19 20-29 30 +
% of cases
Age group (years)
0 doses 1 dose 2 or more doses Unknown
Supplementary immuniza�on ac�vi�es
Year Target age Vaccine used % Coverage
2017 4-18Y MMR 95.2%
2016 27-37Y MR 80%
MMR = measles-mumps-rubella vaccine ND = Data not available
2
Suspected measles
cases
Confirmed measles cases Discarded as measlesnon-
Measles
incidence Genotypes detected Laboratory Epi- linked Clinically Total
2014 7 0 0 0 0 7 0.0 NA
2015 7 0 0 0 0 7 0.0 NA
2016 17 1 0 0 1 16 0.4 ND
2017 31 12 0 0 12 19 1.4 B3
2018 2738 1367 0 102 1469 1269 517.1 ND
Measles incidence, epidemiologic and virologic
characteristics, 2014-2018 Measles surveillance and laboratory performance indicators, 2014-2018
Source: Measles and rubella elimination Annual Status Update report, 2014-2018 Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable
Source: Measles and rubella elimination Annual Status Update report, 2014-2018 ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory
Rubella incidence, epidemiologic and virologic
characteristics, 2014-2018 Rubella surveillance and laboratory performance indicators, 2014-2018
Source: Measles and rubella elimination Annual Status Update report, 2014-2018 Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable
Source: Measles and rubella elimination Annual Status Update report, 2014-2018 ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory
Surveillance performance indicators and targets
a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population b. % cases with adequate laboratory investigation: ≥ 80%
c. % origin of infection known: ≥ 80%
d. Rate of viral detection: ≥ 80%
Measles and rubella elimination country profile Albania
Discarded non- measles rate
% 1st sub- national unit
with ≥ 2 discarded cases
% cases with adequate laboratory investigation
% origin of infection
known
# specimen tested for measles
% positive for measles
Rate of viral detection
% WHO and proficient
labs
2014 0.3 100% 100% NA 7 0% 0% ND
2015 0.3 100% 100% NA 7 0% 0% 100%
2016 0.6 14% 100% 100% 42 2.4% 0% ND
2017 0.7 22% 100% 100% 31 38.7% 25% 100%
2018 45.3 91.7% 100% 100% 2636 51.90% 100% ND
Suspected rubella
cases
Confirmed rubella cases Discarded non-as rubella
Rubella
incidence Genotypes detected Laboratory Epi- linked Clinically Total
2014 1 0 0 0 0 1 0 NA
2015 3 0 0 0 0 3 0 NA
2016 2 0 0 0 0 2 0 NA
2017 1 0 0 0 0 1 0 NA
2018 0 0 0 0 0 0 0 NA
Discarded non- rubella rate
% 1st sub- national unit
with ≥ 2 discarded
cases
% cases with adequate laboratory investigtion
% origin of infection
known
# specimen tested for rubella
% positive for rubella Rate of viral
detection
% WHO and proficient
labs
2014 0.0 100% 100% NA 1 0% 0% ND
2015 0.1 100% 100% NA 3 0% 0% 100%
2016 0.1 0% 100% NA 42 2.4% 0% ND
2017 0.0 2.8% 100% NA 1 0% NA 100%
2018 0.0 0% 0% NA 0 0% 0% ND
RVC comments, based on 2018 reporting
The RVC commends the country for its efforts in outbreak response and for maintaining high immunization coverage.
However, as the NVC concluded, there is evidence of continuous measles transmission for a period longer than 12 months.
Therefore, measles transmission has been re-established in Albania. The RVC urges the national health authorities to implement WHO strategies and recommendations to control the outbreak, close immunity gaps in the adult population, maintain routine immunization coverage with both MRCV doses >95% and strengthen measures for infection control in health care settings. Efforts should be made also to periodically collect specimens for genotyping, at least every 2 months.
Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: http://www.euro.who.int/8thRVC
© World Health Organization 2020. Some rights reserved.
This work is available under the CC BY-NC-SA 3.0 IGO license.
